Brief: Spago Selects Cmed As CRO For Clinical Trial With Tumorad

Spago Nanomedical AB (publ)

10/11/2021 07:09

Nov 10 (Reuters) - Spago Nanomedical AB (publ)  SPAGO.ST :
    * SPAGO NANOMEDICAL SELECTS CMED AS ITS CRO FOR THE FIRST
CLINICAL
TRIAL WITH TUMORAD®
    * HAS SIGNED AN AGREEMENT WITH GLOBAL CRO CMED GROUP LIMITED
FOR
DEVELOPMENT OF FIRST CLINICAL STUDY WITH COMPANY'S THERAPY
PROJECT TUMORAD

Source text for Eikon:  ID:nMFNc1rllf 
Further company coverage:  SPAGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))